Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens
The program can be an effective early warning system for public health and national security officials, leveraging voluntary nasal and wastewater sampling from international travelers at major
Concentric by Ginkgo, the biosecurity and public health unit of
The program expansion will launch at four of the program's seven major international airports (
The TGS program has proven to be an agile and beneficial asset to public health officials in the United States—quickly adapting to an evolving pandemic in real time since it launched in 2021. As of
"By building sustainable, scalable infrastructure that is capable of detecting biological threats beyond SARS-CoV-2, the TGS program is a global leader in the evolution of biosecurity," said
TGS was among the first to detect many new SARS-CoV-2 variants entering
"With air travel exceeding pre-pandemic levels and the ongoing spread of COVID-19 and other viruses, it is crucial that we continue to test," said XpresCheck CEO
XpresSpais a leading airport retailer of wellness services and related products, with 30 locations in 14 airports globally.
- Treat is a travel wellness brand and a fully integrated concept blending technology with traditional brick and mortar offerings to provide a holistic approach to physical and mental well-being for travelers.
- Naples Wax Center is a group of upscale skin care boutiques in
Floridaand represents the first step in building the Company's retail portfolio outside the airport.
- XpresCheck is a provider of screening and diagnostic testing in partnership with the
CDCand Concentric by Ginkgo, conducting bio-surveillance monitoring in its airport locations to identify new SARS-CoV2 variants of interest and concern as well as other pathogens entering the country from across the world.
- HyperPointe is a leading digital healthcare and data analytics relationship company serving the global healthcare industry.
Forward-Looking Statements of XWELL, Inc.
This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events, including the Company's current plans and expectations relating to the business and operations and future store openings for Naples Wax Center, are based upon information available to XWELL as of today's date and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other
Forward-Looking Statements of
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's biosecurity platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the
GINKGO BIOWORKS INVESTOR CONTACT:
GINKGO BIOWORKS MEDIA CONTACT:
XWELL MEDIA CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-xwell-implement-expanded-cdc-traveler-based-genomic-surveillance-program-to-test-for-more-than-30-known-pathogens-301977874.html